GOAL: To determine if abolishing the Nedd4-2 recognition site in mice using the Scn1aY1986A allele rescues Scn1a+/- Dravet syndrome phenotypes by increasing steady-state Nav1.1 levels.
|Effective start/end date||4/12/16 → 4/12/17|
- Xenon Pharmaceuticals Inc. (Agmt 4/12/16)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.